Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds.

EVIAGENICS is a biotechnology company generating new products and improved manufacturing processes for the chemical and pharmaceutical industry by applying its unique in vivo recombination technology. After the successful validation of the technology in several collaborations with industrial partners from red and white biotechnology EVIAGENICS will focus its activities on the development of a technology platform for the efficient recombination and expression of metabolic pathways in cells. These reprogrammed cells will be able to transform sugars from cheap renewable sources like feedstock into numerous new high value compounds.

Weyerhaeuser NR Co., part of Weyerhaeuser Co., is an American company located in Federal Way, WA, that provides real estate services.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.

Revivicor is a regenerative medicine company focused on applying leading-edge animal biotechnology platforms to provide a superior quality, high-volume, human-compatible, alternative tissue source for treatment of human degenerative disease.

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for fluid cell count and analysis. It operates through the following segments: Instruments, Consumer Goods, Service, and Others. The Instruments segment sells NucleoCounter NC-100, NC-200, NC250, and NC-3000. The Consumer Goods segment offers disposable cartridges, disposable analysis chambers, reagents, and test kits. The Service segment provides service packages and its corresponding guarantees. The Others segment offers measuring modules and accessories. The company was founded by Hans Martin Glensbjerg in 1977 and is headquartered in Allerod, Denmark.

Weyerhaeuser Co. engages in the manufacture, distribution, and sale of forest products. It operates through the following business segments: Timberlands, Real Estate, Energy and Natural Resources (Real Estate & ENR), and Wood Products. The Timberlands segment manages private commercial forestland worldwide, engages in growing and harvesting trees for lumber, building, pulp, paper and other wood products. The Real Estate and ENR segment delivers premiums to timber value by identifying and monetizing higher and better use lands and capturing the full value of surface and subsurface assets. The Wood Products segment delivers lumber, structural panels, engineered wood products and complementary building products for residential, multi-family, industrial and light commercial applications. The company was founded by Frederick Weyerhaeuser on January 18, 1900 and is headquartered in Seattle, WA.

Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions

Consiglio Nazionale delle Ricerche is the largest public research facility in Italy. Founded in 1923, it has worked in the past as a government consultant on research and as a funding fund for university research grants. Since 1989 the CNR is a research institution, with the mission of carrying out research projects, promoting innovation and competitiveness of the national industrial system, the internationalization of the national research system, and providing technologies and solutions to emerging needs in the public and private sectors. . Objectives that are achieved through a wealth of human resources that has over 8000 employees, half of which is represented by researchers and technologists. About 4,000 young researchers are involved in post-doctoral research activities in the laboratories of the Institute, while an important contribution comes from collaborations, including international ones, with researchers from universities and companies, thus strengthening the national research system.

Nexell Therapeutics, Inc. operates as a biotechnology company whose principal subsidiary, Nexell of California, Inc. (NCI) engages in the development of cell therapy products for the treatment of genetic blood disorders, autoimmune diseases, cancer and regenerative medicine applications. Its lead candidate product in Phase III clinical trials is a proprietary cellular product comprised of CD34+ hematopoietic stem cells (HSC) for treatment of chronic granulomatous disease, a life-threatening hereditary disorder. NCI is also developing dendritic cell vaccines for the treatment of certain cancers. In this program, NCI is applying proprietary technology to isolate dendritic cell precursors, activate them ex vivo and transform them into mature dendritic cells suitable for reinfusion into the patient. The initial candidate vaccine is targeting colon cancer. Also, NCI has a preclinical development program for a companion to the HSC stem cell product that is intended for stabilization and maintenance of donor cells.

ArborGen, Inc. develops biotechnology tree seedling products. It also provides conventional and technology enhanced seedlings to the forestry industry. The firm's seedling products span the entire technology spectrum, from conventional seedlings to biotechnology seedlings. The company was founded on February 7, 2000 and is headquartered in Ridgeville, SC.

CellFor is the world's leading independent supplier of high technology seedlings to the global forest industry. Using plant biotechnology, which is the use of biological processes to manufacture products, CellFor identifies and produces genetically superior conifer seedlings without genetic modification.\nIt's not a position they have earned by being the biggest seedling producer in the world, but by being the first to tap into the promise of plant biotechnology to mass produce high quality, top performing conifer seedlings more quickly, more dependably, and in far greater quantities than ever before.\nCellFor corporate headquarters is based in Vancouver, British Columbia, with the primary research and development, laboratory and production facilities located north of Victoria, on Vancouver Island. They have more than 200 scientists and technicians at their facilities in and around Victoria, where they are producing somatic embryos and seedlings on a commercial scale for customers in North America, South America and Australasia. In addition, CellFor has a Sales and Marketing team located in Atlanta, Georgia.

Shenzhen Super Life Technology Co., Ltd., established on 2016-04-26, Business scope includes general business items:Technology development in the field of computer science and technology,Technical Services,technical consulting,technology transfer,Technical maintenance and technical sales;Computer hardware and software development and maintenance;Chemical Products(Free of Hazardous Chemicals)promotion of;Technical development of instrumentation and chemical reagents;Computer Equipment and Accessories,Equipment,electronic product,Building Intelligent System,Sales of security electronic systems;Network Engineering Design,construction;water treatment equipment,refrigeration equipment,Electrical Equipment,Sales of industrial automation equipment and accessories;Installation and maintenance of industrial automation equipment;Invest in business(Specific projects will be reported separately);investment management,Investment Advisory,Investment Advisor;Research and development of sexual health products,Wholesale and retail(above according to the law,Administrative regulations,Decisions of the State Council and other regulations that require approval,Can only operate after obtaining relevant approval documents according to law).,The licensing program is:Production of sexual health products;Electrical equipment installation and maintenance.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

AXON is R&D based drug discovery Biotechnology Company and its main competences are in discovery and validation of novel disease targets and development of therapeutics for AD. Its major asset is an integrated discovery and validation platform based on tau pathology. AXON's unique proprietary disease models allow rapid identification and validation of new disease targets and biomarkers. The company is a leader in understanding the molecular aspects of tau-associated pathological processes in AD, which allow for identification of disease-specific therapeutic targets. AXON holds intellectual property rights to the drug target (Alzheimer truncated tau) and to the rat models for AD and human tauopathies.\nAXON Neuroscience is headquartered in the Campus Vienna Biocenter (VBC), Vienna, Austria. The Vienna facility features state-of-the-art technologies for high throughput screening, biochemistry and molecular biology laboratories. The AXON subsidiary complements with in vivo techniques including behavioral phenotyping of animal models, transgenesis, electrophysiology, pre-clinical drug testing, cell biology and immunology units with monoclonal antibody production.

Syngenta AG is a global company that produces agrochemicals and seeds and is based in Basel, Switzerland. As a biotechnology company, it conducts genomic research. It was formed in 2000 by the merger of Novartis Agribusiness and Zeneca Agrochemicals. As of 2014 Syngenta is the world’s largest crop chemical producer As of 2009 it ranked third in seeds and biotechnology sales. Sales in 2015 were approximately US$13.4 billion, over half of which were in emerging markets. It is owned by ChemChina, a Chinese state-owned enterprise.

Part of Istrokapital SE, AXON Neuroscience SE is a Cypriot company located in Larnaca that provides research and development services. It was founded in 1999 by Michal Novak. Michal Fresser has been the CEO since 2013.

Spectros Corp. develops, markets, and licenses medical devices based on in vivo molecular optical technologies, including clinical devices for detection of ischemia and cancer. Its medical devices utilize optical technologies that speed diagnosis, enable real-time therapies and reduce complications. The company's flagship product, the T-Stat Tissue Oximeter, is a medical device that is sensitive to ischemia, an insufficient supply of oxygen to tissue. The firm is also developing molecular imaging contrast agents for surgical guidance during breast and prostate cancer surgeries. Spectros was incorporated on April 19, 1995 and is headquartered in Portola Valley, CA.